21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing]
RxCUI: 1367439
What the CMS Formulary Data Shows for 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing]
Per the CMS 2026 Part D formulary file, 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] (RxNorm concept RXCUI 1367439) appears on 2 distinct formulary files spanning 3 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 2, with a cross-plan average of Tier 1.5.
Real-world access to 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 164 Part D beneficiaries filled 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] in 2023, with total plan-and-beneficiary spending of $196,550 and an average per-beneficiary annual cost of $1,198.48. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 3
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 2
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 164
- Total spending
- $196,550
- Avg per beneficiary
- $1,198.48
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing]
3 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
| CalOptima Health OneCare Complete (HMO D-SNP) | ORANGE COUNTY HEALTH AUTHORITY | T2 | No | $0 | CA |
Frequently Asked Questions
Is 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] covered by Medicare Part D?
Yes, 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] is covered by 3 Medicare Part D plans (0.1% of all Part D formularies).
What tier is 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] on Medicare Part D plans?
21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] averages Tier 1.5 across Part D plans, ranging from Tier 1 to Tier 2.
Does 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] require prior authorization?
0% of Part D formularies require prior authorization for 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing]?
In 2023, total Medicare Part D spending on 21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [NuvaRing] was $196,550, covering 164 beneficiaries. The average spend per beneficiary was $1,198.48.
Read our methodology - how this data is sourced, computed, and verified.